Search results for:
Ondine reports successful US Phase 2 trial data
Ondine Biomedical reports successful topline data from Phase 2 nasal photodisinfection trial Vancouver, British Columbia, Canada - September 6, 2022 Results show a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in pre-surgical patients Top line results [...]
Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients
Nature publication reports that Ondine’s nasal antimicrobial photodynamic disinfection therapy suppresses SARS-CoV-2 in COVID-19 patients Vancouver, British Columbia, Canada - August 31, 2022 The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), [...]
Ondine completes enrollment for US Phase II nasal photodisinfection trial
Ondine Biomedical completes patient recruitment for US Phase II nasal photodisinfection trial Vancouver, British Columbia, Canada - August 8, 2022 Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s [...]
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Suppression of SARS-CoV-2 replication and infectivity in vaccinated individuals: a clinical study of Ondine Biomedical’s nasal photodisinfection carried out at the Clínica Universidad de Navarra, Spain Vancouver, British Columbia, Canada - July 19, 2022 Clínica Universidad de Navarra has completed a randomised controlled study of Ondine [...]
WHO calls for new innovations to tackle antimicrobial resistance crisis
WHO calls for new innovations to tackle antimicrobial resistance crisis Vancouver, British Columbia, Canada - July 6, 2022 Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has [...]
Photodisinfection effective against SARS-CoV-2
New study confirms that photodisinfection is rapidly effective against SARS-CoV-2 Vancouver, British Columbia, Canada - April 5, 2022 Ondine Biomedical (AIM: OBI) announces that independent research has confirmed previous results showing that Ondine Biomedical’s photodisinfection technology is highly effective against human clinical isolates of SARS-CoV-2. [...]
First patients treated in US Phase 2 trial
Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections Vancouver, British Columbia, Canada - February 7, 2022 Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare [...]
Ondine COVID-19 clinical trial in Spain begins patient recruitment
Ondine Biomedical Inc. and University of Navarra in Spain initiate clinical trial deploying nasal photodisinfection for a new variant-agnostic approach to stop SARS-CoV-2 replication in high-risk viral carriers Vancouver, British Columbia, Canada - December 20, 2021 Nasal decolonisation therapy, Steriwave™, destroys all pathogen classes, including [...]
Sinuwave Receives IPA President’s Choice Award
Ondine Biomedical Subsidiary Receives 2019 President’s Choice Award at the 17th World Congress of the International Photodynamic Association VANCOUVER, BRITISH COLUMBIA, CANADA - July 12, 2019 Sinuwave Technologies Corporation, a subsidiary of Ondine Biomedical Inc., was honoured with the 2019 President’s [...]
For Media Information
Simon Vane Percy
Amanda Bernard
